CLINICAL OUTCOMES OF USE OF HYDROXYCHLOROQUINE IN PARADOXICAL TUBERCULOSIS-IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV-INFECTED PATIENTS.

Pramod Kumar A; Parthasarathi G; Mothi Sn; Sudheer Ap; Vht Swamy; Sri Rama

doi:10.22159/ajpcr.2018.v11i2.21995

Authors

Pramod Kumar A Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Mysore, Karnataka, India.
Parthasarathi G Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Mysore, Karnataka, India.
Mothi Sn Department of Infectious Diseases,Asha Kirana Hospital, Centre for AIDS Care and Research Center, Mysore, Karnataka, India.
Sudheer Ap Department of Infectious Diseases,Asha Kirana Hospital, Centre for AIDS Care and Research Center, Mysore, Karnataka, India.
Vht Swamy Department of Infectious Diseases,Asha Kirana Hospital, Centre for AIDS Care and Research Center, Mysore, Karnataka, India.
Sri Rama Department of Infectious Diseases,Asha Kirana Hospital, Centre for AIDS Care and Research Center, Mysore, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i2.21995

Keywords:

Hydroxychloroquine, Immune reconstitution inflammatory syndrome, HIV, Tuberculosis

Abstract

Â Objective: Immune reconstitution inflammatory syndrome (IRIS) is an inflammatory reaction in HIV-infected patients after initiation of antiretroviral therapy (ART) resulting from restored immunity to specific infectious or non-infectious antigens. The most common condition where IRIS has been reported is tuberculosis (TB). Various mechanisms have been proposed and studied to account for the immune regulatory role of hydroxychloroquine (HCQ). This study is done to identify clinical outcome in HIV-TB patients with IRIS after given with HCQ.

Methods: An uncontrolled longitudinal study was conducted among HIV-infected patients with TB initiated on ART and developed IRIS between July 2013 and June 2015 in a South Indian HIV care hospital.

Results: A total of 40 patients have developed IRIS with mean age of 35.87 years and 77.5 % of them were males. At the time of IRIS occurrence, the mean body mass index was found to be 19.17 kg/m2 and CD4 count was 200 cells/mm3. The time duration took to get improvement in majority of the patients was 4â€“12 weeks.

Conclusion: There was definite improvement seen in patients who received HCQ in TB-IRIS condition.

Downloads

Download data is not yet available.

References

Suzaan M, Robert J, Dominique J, Graeme M. Management of Patients with Immune Reconstitution Inflammatory Syndrome. Complication of HIV Infection and Treatment Current HIV/AIDS Reports; 2009. p. 171-180.

Riddell JT, Daniel RK, Petros CK, Joel EG, Jennifer M, Powel H. Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes. J Transl Med 2007;5:50.

Swati P, Pankaj K, Vinod R. Bioenhancement effect of piperine and ginger oleo resin on the bioavailability of atazanvir. Int J Pharm Pharm Sci 2015;7:241-5.

French MA. HIV/AIDS: Immune reconstitution inflammatory syndrome: A reappraisal. Clin Infect Dis 2009;48:101-7.

French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-15.

Kumar AP, Prasad SR, Parthasarathi G, Krishna U. Management of immune reconstitution inflammatory syndrome in HIV patients. Int J Univ Pharm Biosci 2016;5:303-11.

Kumar AP, Sarathi GP, Sudheer AP, Mothi SN, Swamy VH, Rao S. Incidence and risk factors of renal impairment in HIV-1 infected patients receiving tenofovir based antiretroviral therapy in a South Indian hospital. Int J Pharm Pharm Sci 2017;9:152-5.

Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W, et al. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998;274:R1058-64.

Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993;9:91-8.

Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010;84:12082-6.

Stefania P, Serena P, Giuliano R, Simone P, Roberta T, Barbara A, et al. Hydroxychloroquine drastically reduces immune activation in HIV infected, ART-treated, immunological non responders. Blood J Hematol Lib Org 2014;118:3263-72.

Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006;4:469-78.

AIDS Info: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Available from: http://www.AIDSinfo.nih.gov.